Panbela Therapeutics (PBLA) Competitors $0.34 +0.02 (+5.26%) As of 03/25/2025 02:56 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsTrendsBuy This Stock PBLA vs. BFRI, KLTO, JAGX, AYTU, CELZ, BTAI, ONVO, BGXX, OMGA, and CYCNShould you be buying Panbela Therapeutics stock or one of its competitors? The main competitors of Panbela Therapeutics include Biofrontera (BFRI), Klotho Neurosciences (KLTO), Jaguar Health (JAGX), Aytu BioPharma (AYTU), Creative Medical Technology (CELZ), BioXcel Therapeutics (BTAI), Organovo (ONVO), Bright Green (BGXX), Omega Therapeutics (OMGA), and Cyclerion Therapeutics (CYCN). These companies are all part of the "pharmaceutical products" industry. Panbela Therapeutics vs. Biofrontera Klotho Neurosciences Jaguar Health Aytu BioPharma Creative Medical Technology BioXcel Therapeutics Organovo Bright Green Omega Therapeutics Cyclerion Therapeutics Biofrontera (NASDAQ:BFRI) and Panbela Therapeutics (NASDAQ:PBLA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, community ranking, risk, profitability, valuation and earnings. Does the media refer more to BFRI or PBLA? In the previous week, Biofrontera had 11 more articles in the media than Panbela Therapeutics. MarketBeat recorded 11 mentions for Biofrontera and 0 mentions for Panbela Therapeutics. Biofrontera's average media sentiment score of 0.67 beat Panbela Therapeutics' score of 0.00 indicating that Biofrontera is being referred to more favorably in the media. Company Overall Sentiment Biofrontera Positive Panbela Therapeutics Neutral Do insiders and institutionals hold more shares of BFRI or PBLA? 10.1% of Biofrontera shares are held by institutional investors. Comparatively, 4.4% of Panbela Therapeutics shares are held by institutional investors. 0.2% of Biofrontera shares are held by insiders. Comparatively, 0.0% of Panbela Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has higher earnings and valuation, BFRI or PBLA? Biofrontera has higher revenue and earnings than Panbela Therapeutics. Biofrontera is trading at a lower price-to-earnings ratio than Panbela Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiofrontera$35.36M0.20-$20.13M-$2.26-0.40Panbela TherapeuticsN/AN/A-$25.26M-$71.130.00 Is BFRI or PBLA more profitable? Panbela Therapeutics has a net margin of 0.00% compared to Biofrontera's net margin of -36.31%. Panbela Therapeutics' return on equity of 0.00% beat Biofrontera's return on equity.Company Net Margins Return on Equity Return on Assets Biofrontera-36.31% -565.73% -96.64% Panbela Therapeutics N/A N/A -302.61% Which has more risk & volatility, BFRI or PBLA? Biofrontera has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500. Comparatively, Panbela Therapeutics has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500. Do analysts rate BFRI or PBLA? Biofrontera presently has a consensus target price of $7.00, indicating a potential upside of 677.78%. Given Biofrontera's stronger consensus rating and higher possible upside, research analysts plainly believe Biofrontera is more favorable than Panbela Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biofrontera 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Panbela Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the MarketBeat Community favor BFRI or PBLA? Panbela Therapeutics received 10 more outperform votes than Biofrontera when rated by MarketBeat users. However, 66.67% of users gave Biofrontera an outperform vote while only 62.07% of users gave Panbela Therapeutics an outperform vote. CompanyUnderperformOutperformBiofronteraOutperform Votes866.67% Underperform Votes433.33% Panbela TherapeuticsOutperform Votes1862.07% Underperform Votes1137.93% SummaryBiofrontera beats Panbela Therapeutics on 11 of the 16 factors compared between the two stocks. Remove Ads Get Panbela Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PBLA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PBLA vs. The Competition Export to ExcelMetricPanbela TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.65M$6.99B$5.68B$8.30BDividend YieldN/A2.72%4.55%4.02%P/E Ratio0.007.2324.5519.25Price / SalesN/A230.77395.7294.10Price / CashN/A65.6738.1634.64Price / Book-0.026.617.064.46Net Income-$25.26M$142.13M$3.19B$247.07M7 Day Performance-16.05%1.72%0.18%1.77%1 Month Performance-18.07%2.31%5.54%-3.31%1 Year Performance-46.88%-5.07%14.22%5.26% Panbela Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PBLAPanbela TherapeuticsN/A$0.34+5.3%N/A-46.9%$1.65MN/A0.006BFRIBiofrontera2.9418 of 5 stars$1.01+9.1%$7.00+593.1%-23.7%$7.83M$35.36M-0.4570KLTOKlotho NeurosciencesN/A$0.29+1.6%N/AN/A$7.79MN/A0.00N/APositive NewsGap UpJAGXJaguar Health0.0497 of 5 stars$0.47+5.4%N/A+24.9%$7.69M$10.48M0.0050AYTUAytu BioPharma1.114 of 5 stars$1.23+2.0%N/A-58.6%$7.58M$77.23M-0.85160Positive NewsGap UpHigh Trading VolumeCELZCreative Medical Technology0.4984 of 5 stars$3.21-1.8%N/A-59.4%$7.46M$11,000.00-0.845Upcoming EarningsAnalyst RevisionNews CoverageGap DownHigh Trading VolumeBTAIBioXcel Therapeutics4.4751 of 5 stars$2.28+7.0%$37.00+1,522.8%-95.1%$7.31M$2.28M-0.0790ONVOOrganovo0.4278 of 5 stars$0.43+0.4%N/A-77.0%$7.31M$122,000.00-0.5020Stock SplitBGXXBright GreenN/A$0.04+10.3%N/A-73.2%$7.17MN/A-0.632Gap UpOMGAOmega Therapeutics1.9775 of 5 stars$0.13-21.8%$9.20+7,260.0%-96.3%$6.92M$8.10M-0.09120Upcoming EarningsGap UpCYCNCyclerion Therapeutics0.5321 of 5 stars$2.55+0.8%N/A-10.2%$6.91M$2M-2.0930 Remove Ads Related Companies and Tools Related Companies Biofrontera Competitors Klotho Neurosciences Competitors Jaguar Health Competitors Aytu BioPharma Competitors Creative Medical Technology Competitors BioXcel Therapeutics Competitors Organovo Competitors Bright Green Competitors Omega Therapeutics Competitors Cyclerion Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PBLA) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Panbela Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Panbela Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PBLA Stock Free PBLA Stock Alerts